UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.
FOR PATIENTS LIKE…
separator
FOR PATIENTS LIKE…
separator
FOR PATIENTS LIKE…
Diagnosed with migraine 2 years ago.
Symptoms: Increased headache intensity and duration over the last year.
Considerations: Marnie has been self-managing her headaches with OTC medications.
Diagnosed with migraines 6 years ago.
Symptoms: Moderate to severe throbbing pain about once a week.
Considerations: Jennifer has expressed tolerability concerns relating to medication.
separator
SAFETY INFORMATION
Click here for additional safety information and for a link to the Product Monograph discussing:
●Contraindications with concomitant use of strong CYP3A4 inhibitors.
●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.
●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
FOR MORE INFORMATION
For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011.
SAFETY INFORMATION
Click here for additional safety information and for a link to the Product Monograph discussing:
●Contraindications with concomitant use of strong CYP3A4 inhibitors.
●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.
●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
FOR MORE INFORMATION
For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011.
SAFETY INFORMATION
Click here for additional safety information and for a link to the Product Monograph discussing:
●Contraindications with concomitant use of strong CYP3A4 inhibitors.
●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breast-feeding women and dose selection in geriatric patients.
●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
FOR MORE INFORMATION
For any questions related to UBRELVY, you can contact AbbVie Medical Information at
1-844-241-5011.
*Fictitious case. May not be representative of general population.
*Fictitious case. May not be representative of general population.
UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CA-UBR-230004A / JN24
UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CA-UBR-230004A / JN24